United Therapeutics counsel exercises options, sells shares
United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share and sold 8,300 shares in multiple open-market trades at prices between $527.5950 and $536.8526.
Rhea-AI Filing Summary
United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share and sold 8,300 shares in multiple open-market trades at prices between $527.5950 and $536.8526. These trades were executed under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025, and Mahon continues to hold 80,740 stock options afterward.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,300 shares ($3.22M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
MAHON PAUL A
Role
EVP & GENERAL COUNSEL
Sold
8,300 shs ($4.43M)
Approx. gross sale proceeds
$4.43M
Approx. exercise cost
$1.21M
Approx. pre-tax spread
$3.22M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1 | 8,300 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 8,300 | $146.03 | $1.21M |
| Sale | Common Stock F1 | 600 | $527.595 | $317K |
| Sale | Common Stock F1 | 120 | $529.81 | $64K |
| Sale | Common Stock F1, F2 | 861 | $531.9692 | $458K |
| Sale | Common Stock F1, F3 | 800 | $532.9394 | $426K |
| Sale | Common Stock F1, F4 | 3,279 | $534.2114 | $1.75M |
| Sale | Common Stock F1, F5 | 1,041 | $535.8798 | $558K |
| Sale | Common Stock F1, F6 | 1,519 | $534.9891 | $813K |
| Sale | Common Stock F1, F7 | 80 | $536.8526 | $43K |
Holdings After Transaction:
Stock Option — 80,740 contracts (Direct);
Common Stock — 45,172 shares (Direct)
Footnotes (7)
- F1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $531.50 to $532.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $532.51 to $533.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $533.56 to $534.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $535.565 to $536.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $534.56 to $535.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $536.75 to $536.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 8,300 shares
Options exercised: 8,300 shares
Exercise price: $146.0300 per share
+3 more
6 metrics
Shares sold
8,300 shares
Total United Therapeutics common shares sold in open-market transactions on 2026-07-16
Options exercised
8,300 shares
Common shares received upon exercise of stock options on 2026-07-16
Exercise price
$146.0300 per share
Conversion or exercise price of the stock options exercised for 8,300 shares
Sale price range
$527.5950–$536.8526 per share
Price range across reported open-market sales of common stock on 2026-07-16
Options held after transaction
80,740 options
Stock options reported as beneficially owned after the derivative transaction
10b5-1 plan date
August 11, 2025
Date the pre-arranged Rule 10b5-1 trading plan was entered into by the reporting person
Key Terms
Rule 10b5-1 plan, derivative security, weighted average price, stock options
4 terms
Rule 10b5-1 plan regulatory
"This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"This is an exercise of stock options and sale of the resulting shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did United Therapeutics (UTHR) executive Paul A. Mahon report on 2026-07-16?
Paul A. Mahon exercised 8,300 stock options and sold 8,300 United Therapeutics common shares on 2026-07-16. The transactions involved open-market sales at various prices between $527.5950 and $536.8526 per share, all tied to an option exercise and executed under a Rule 10b5-1 plan.
What stock options did Paul A. Mahon exercise in this United Therapeutics (UTHR) insider transaction?
He exercised stock options covering 8,300 shares of United Therapeutics common stock at an exercise price of $146.03 per share. These options are described as a derivative security convertible into common stock, with an original exercise date of 2023-03-15 and expiration on 2027-03-15.
How many United Therapeutics (UTHR) stock options does Paul A. Mahon hold after these transactions?
After the reported transactions, Mahon is shown as holding 80,740 United Therapeutics stock options. This figure reflects his remaining derivative position following the exercise of 8,300 options that converted into common shares on 2026-07-16.
What is the significance of the weighted-average prices in Paul A. Mahon’s UTHR stock sales?
Each reported sale price reflects a weighted-average price for multiple trades within a stated range. Footnotes explain that individual trades occurred at various prices inside those ranges, and detailed trade data can be provided on request to regulators, the issuer, or security holders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
